Capitainer's products cornerstone of COVID-19 study by the Swedish Public Health Agency, published in The Lancet
An increased number of vaccine doses, administrated more frequently, reduces the mortality of COVID-19 in residents of nursing homes. This is demonstrated in a study by the Public Health Agency of Sweden, published in The Lancet. The testing at these nursing homes was performed through self-sampling and assisted sampling using Capitainer's patented sampling cards.
A recently published study demonstrates that administering an increased number of vaccine doses more frequently reduces the mortality rate of COVID-19 among individuals residing in nursing homes. The repeated testing in the study was conducted using the medtech company Capitainer's blood self-sampling product. The study measured the antibody concentration in individuals at 115 nursing homes at intervals of four weeks with three months in between vaccinations, resulting in guidance on how vaccination recommendations can best protect the elderly. The study was conducted by the Public Health Agency of Sweden (Folkhälsomyndigheten) and Umeå University and was published in the esteemed scientific journal The Lancet.
"We are very proud that our sampling solution has formed the basis for this important research. Knowing that our product has been crucial in collecting data and deriving conclusions that make a significant difference in the care of our elderly and most vulnerable citizens feels immensely meaningful," says Christopher Aulin, CEO of Capitainer.
The solution for analyzing antibodies against COVID-19 was developed during the COVID-19 pandemic. It is based on Capitainer's qDBS technology (quantitative Dried Blood Spot) for self-sampling in a home environment, combined with an analysis method developed by the Umeå-based company Xerum. The solution was used during the pandemic by Region Västerbotten to offer self-sampling to the residents and was distributed via the 1177 healthcare service.
“This study stands out due to its dedicated focus on our elderly population and its innovative approach offering individuals the option to take the samples themselves or with the assistance of a family member. The ability to collect samples from large geographic areas in a patient-friendly and convenient manner to create a solid foundation for decision support extends beyond COVID-19 vaccinations. We look forward to continuing to support patients and the healthcare system with our patented sampling products," says Mikael Ström, Business Development Manager at Capitainer."
Capitainer's self-sampling products can serve as a foundation for conducting analyses ranging from diabetes monitoring to medication tracking or antibodies for various diseases. For example, a recent study demonstrated how Capitainer's technology enables the monitoring of medications and biomarkers for kidney transplant patients through self-sampling in their own homes.
The study:
SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters
For more information, please contact:
Christopher Aulin, CEO
Phone: +46 (0)708 977577
Email: aulin@capitainer.se
About Capitainer
Capitainer AB is a Swedish medtech company founded in 2016. Capitainer develops and sells intelligent solutions for self-sampling of blood, plasma, and urine. The company has developed unique technologies for collecting an exact amount of fluid and then allowing it to dry. The sample card can be sent with regular mail to laboratories without needing refrigerated transports or special packaging. The precision and accuracy in Capitainer’s samples are market-leading and perform on the same level as established pipetting methods. The products can be applied within several market segments, for instance, clinical biomarkers, therapeutic drug monitoring, genomics, drug development, drug abuse and doping testing, and R&D and clinical studies.
Tags:
